Document is current
Any future updates will be listed below
-
Authors
James, Scott E. https://orcid.org/0000-0002-3601-6819
Chen, Sophia
Ng, Brandon D.
Fischman, Jacob S.
Jahn, Lorenz https://orcid.org/0000-0002-9880-7026
Boardman, Alexander P. https://orcid.org/0000-0001-7169-9275
Rajagopalan, Adhithi
Elias, Harold K.
Massa, Alyssa
Manuele, Dylan
Nichols, Katherine B. https://orcid.org/0000-0003-0817-1667
Lazrak, Amina
Lee, Nicole
Roche, Aoife M.
McFarland, Alexander G.
Petrichenko, Angelina
Everett, John K.
Bushman, Frederic D. https://orcid.org/0000-0003-4740-4056
Fei, Teng https://orcid.org/0000-0001-7888-1715
Kousa, Anastasia I.
Lemarquis, Andri L.
DeWolf, Susan
Peled, Jonathan U. https://orcid.org/0000-0002-4029-7625
Vardhana, Santosha A.
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
van den Brink, Marcel R. M. https://orcid.org/0000-0003-0696-4401
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA228358, R01-CA228308, P30 CA008748, K08-CA252157)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL123340, R01-HL147584)
- License Information
-
More Information
Article History
Received: 28 June 2023
Accepted: 26 September 2024
First Online: 23 December 2024
Competing interests
: S.E.J., L.J., and M.R.M.v.d.B. are co-inventors on patent applications related to this manuscript (‘Leucine zipper-based compositions and methods of use’, nos. US20210171601A1 (USA), EP3836944A4 (Europe), WO2020037178A1 (WIPO), CA3109630A1 (Canada) and CN112930186A (China); ‘Cell sorting systems and methods of use’, nos. US20210179686A1 (USA), EP3837287A4 (Europe), WO2020037181A2 (WIPO), CA3109635A1 (Canada) and CN112996819A (China)). A.P.B. has consulted for Bristol Myers Squibb and Cancer Study Group, LLC, and has received honoraria from OncLive. F.D.B. is a founder of Biocept and has intellectual property licensed to Novartis. J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics as well as consulting fees from Da Volterra, CSL Behring and MaaT Pharma. He serves on an Advisory board of, and holds equity in, Postbiotics Plus Research. He has filed intellectual property applications related to the microbiome. S.A.V. has received funding from Bristol-Meyers Squibb and has received consulting fees from Koch Disruptive Technologies and Generate Biomedicine. C.A.K. has previously filed intellectual property applications related to the FasDNR featured in this manuscript. C.A.K. is a scientific co-founder and holds equity in Affini-T Therapeutics. C.A.K. has previously consulted for or is on the scientific and/or clinical advisory boards of: Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech, Royalty Pharma and T-knife. M.R.M.v.d.B. has received research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; has received royalties from Wolters Kluwer; has consulted, received honoraria from or participated in advisory boards for Seres Therapeutics, Vor Biopharma, Rheos Medicines, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Ceramedix, Lygenesis, Pluto Therapeutics, GlaxoSmithKline, Da Volterra, Thymofox, Garuda, Novartis (spouse), Synthekine (spouse), Beigene (spouse), Kite (spouse); has intellectual property licensing with Seres Therapeutics and Juno Therapeutics; and holds a fiduciary role on the Foundation Board of DKMS (a non-profit organization). MSKCC has institutional financial interests relative to Seres Therapeutics.
